HealthEquity, Inc. (HQY) Downgraded by Zacks Investment Research
Zacks Investment Research lowered shares of HealthEquity, Inc. (NASDAQ:HQY) from a buy rating to a hold rating in a research note published on Friday.
According to Zacks, “HealthEquity, Inc. is a technology-enabled services platforms that empower consumers to make healthcare saving and spending decisions. The Company’s platform provides an ecosystem where consumers can access their tax-advantaged healthcare savings, compare treatment options and pricing, evaluate and pay healthcare bills, receive personalized benefit and clinical information, earn wellness incentives, and make educated investment choices to grow their tax-advantaged healthcare savings. HealthEquity, Inc. is headquartered in Draper, Utah. “
HQY has been the subject of several other reports. BidaskClub upgraded HealthEquity from a sell rating to a hold rating in a report on Thursday, September 28th. Oppenheimer Holdings, Inc. reiterated a buy rating and issued a $61.00 price objective on shares of HealthEquity in a report on Wednesday, September 6th. Cantor Fitzgerald reiterated a buy rating and issued a $56.00 price objective on shares of HealthEquity in a report on Tuesday, August 29th. Robert W. Baird reiterated a hold rating on shares of HealthEquity in a report on Thursday, September 21st. Finally, TheStreet upgraded HealthEquity from a c rating to a b rating in a report on Monday, July 31st. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. HealthEquity has a consensus rating of Buy and a consensus price target of $57.17.
Shares of HealthEquity (NASDAQ HQY) opened at $50.81 on Friday. HealthEquity has a twelve month low of $30.34 and a twelve month high of $54.95. The company has a market capitalization of $3,073.43, a PE ratio of 80.65, a P/E/G ratio of 2.23 and a beta of 1.77.
HealthEquity (NASDAQ:HQY) last released its quarterly earnings data on Tuesday, September 5th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.14 by $0.13. HealthEquity had a return on equity of 13.93% and a net margin of 20.27%. The company had revenue of $56.90 million during the quarter, compared to the consensus estimate of $55.66 million. During the same period last year, the company earned $0.16 EPS. HealthEquity’s revenue for the quarter was up 28.7% on a year-over-year basis. equities analysts expect that HealthEquity will post 0.7 EPS for the current year.
In other news, VP Jon Soldan sold 25,000 shares of HealthEquity stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $40.68, for a total transaction of $1,017,000.00. Following the transaction, the vice president now directly owns 30,652 shares of the company’s stock, valued at approximately $1,246,923.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Stephen Neeleman sold 8,500 shares of HealthEquity stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $46.65, for a total value of $396,525.00. Following the transaction, the insider now directly owns 1,000 shares in the company, valued at $46,650. The disclosure for this sale can be found here. Insiders sold 733,083 shares of company stock worth $37,471,827 over the last three months. Insiders own 19.00% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. Oppenheimer Asset Management Inc. purchased a new position in shares of HealthEquity during the 1st quarter valued at about $106,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of HealthEquity by 105.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,544 shares of the company’s stock valued at $127,000 after buying an additional 1,308 shares in the last quarter. Riverhead Capital Management LLC lifted its position in shares of HealthEquity by 75.3% during the 2nd quarter. Riverhead Capital Management LLC now owns 2,629 shares of the company’s stock valued at $131,000 after buying an additional 1,129 shares in the last quarter. Exane Derivatives purchased a new position in shares of HealthEquity during the 2nd quarter valued at about $132,000. Finally, Fortaleza Asset Management Inc. purchased a new position in shares of HealthEquity during the 2nd quarter valued at about $138,000. 91.40% of the stock is currently owned by hedge funds and other institutional investors.
HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for HealthEquity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.